Literature DB >> 33660126

ASO Author Reflections: Disparities in Outcome and Surgical Management Following Neoadjuvant Chemotherapy for Breast Cancer.

Theresa Relation1, Bridget A Oppong2.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 33660126      PMCID: PMC7927762          DOI: 10.1245/s10434-021-09680-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


× No keyword cloud information.

Past

While breast cancer is the most commonly diagnosed cancer among women, the burden of disease disproportionately falls on Black women, who are more frequently diagnosed at advanced stages and have higher mortality rates. Previous studies have identified socioeconomic barriers to treatment and diagnosis, higher rates of aggressive tumor phenotypes, and earlier age of onset as factors contributing to this observed disparity.1 While neoadjuvant chemotherapy (NAC) has proven useful in reducing overall morbidity and mortality among breast cancer patients, White women are more likely to complete NAC treatment, and Black women are more likely to experience nodal recurrence after NAC.2 Combined, these observed patterns demonstrate a significant and concerning outcome disparity between non-Hispanic White and Black patients.

Present

Our analysis revealed a continuing pattern of adverse socioeconomic variables in Black women, including lower income, educational attainment, and rates of insurance coverage. In examining tumor and clinical features, Black women showed a higher proportion of advanced disease, more poorly differentiated tumors, lower response rates to chemotherapy, and lower likelihood of receiving immunotherapy. White women were more likely to receive breast-conserving surgery and sentinel lymph node biopsy versus axillary lymph node dissection (ALND).3 The disproportionate use of ALND in Black women is a disconcerting finding considering the higher complication rates, especially lymphedema.

Future

The devastating impact of COVID-19 on minority communities has forced us to confront health disparities across many diseases, including breast cancer.4 There remains an urgent need to investigate differences in outcome and understand the factors contributing to disparities. Future interventions must be directed by qualitative studies focused on elucidation of patient preferences, cultural beliefs, and surgeon practice patterns to address disparate treatment. A challenge for healthcare providers is to analyze our own clinical decision-making to recognize the unconscious biases that lead to inequity.
  3 in total

1.  Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base.

Authors:  Brigid K Killelea; Vicky Q Yang; Shi-Yi Wang; Brandon Hayse; Sarah Mougalian; Nina R Horowitz; Anees B Chagpar; Lajos Pusztai; Donald R Lannin
Journal:  J Clin Oncol       Date:  2015-11-23       Impact factor: 44.544

Review 2.  Understanding and effectively addressing breast cancer in African American women: Unpacking the social context.

Authors:  David R Williams; Selina A Mohammed; Alexandra E Shields
Journal:  Cancer       Date:  2016-02-29       Impact factor: 6.860

3.  Purposeful surgical delay and the coronavirus pandemic: how will black breast cancer patients fare?

Authors:  Samilia Obeng-Gyasi; Bridget Oppong; Electra D Paskett; Maryam Lustberg
Journal:  Breast Cancer Res Treat       Date:  2020-06-16       Impact factor: 4.872

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.